• Policy
• Boryung’s Pomalyst generic soon to be released
• by Lee, Tak-Sun Jan 14, 2025 05:57am

• Opinion
• [Reporter's View] K-Bio's development and human resource
• by Whang, byung-woo Jan 14, 2025 05:56am

• Opinion
• [Reporter’s View] Korean drugs go international this year
• by Son, Hyung Min Jan 14, 2025 05:56am

• Company
• 'Leclaza·Rybrevant comb therapy' wins nod in KOR
• by Son, Hyung Min Jan 14, 2025 05:56am

• Company
• Samsung Bioepis partners with Teva for Soliris biosimilar
• by Cha, Jihyun Jan 14, 2025 05:56am

• Company
• Will biotech companies continue 'K-Bio' success?
• by Moon, sung-ho Jan 13, 2025 05:53am

• Company
• Samsung Bioepis to indirectly sell Soliris biosimilar in US
• by Cha, Jihyun Jan 13, 2025 05:53am

• Company
• Wegovy can be prescribed in tertiary hospitals in KOR
• by Eo, Yun-Ho Jan 13, 2025 05:53am

• Policy
• Will 'Lorviqua' secure a deal on drug price negotiations?
• by Lee, Tak-Sun Jan 13, 2025 05:53am

• Policy
• New criteria set for unstable supply and demand drugs
• by Lee, Tak-Sun Jan 13, 2025 05:53am